News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
US Panel Rejects Genentech, Inc.'s Avastin for Treating Breast Cancer
December 5, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
GAITHERSBURG, Md., Dec 5 (Reuters) - Cancer drug Avastin should not be approved to treat women with breast cancer, a U.S. advisory panel recommended on Wednesday.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Postmarket research
FDA
Approvals
Genentech, Inc.
MORE ON THIS TOPIC
Drug Development
Biogen’s Alzheimer’s results bolster tau theory—and Denali’s next gen candidate
May 15, 2026
·
3 min read
·
Annalee Armstrong
Insights
GPCRs, radiopharma and the rise of functional peptide screening
May 14, 2026
·
3 min read
·
Jennifer C. Smith-Parker
Gene therapy
REGENXBIO slumps after serious side effects mar Duchenne gene therapy results
May 14, 2026
·
3 min read
·
Annalee Armstrong
Alzheimer’s disease
Biogen takes tau Alzheimer’s therapy to Phase 3 despite mid-stage fail, prompting cautious optimism
May 14, 2026
·
3 min read
·
Tristan Manalac